البيانات الصحفية والأخبار

Apr 23, 2025

PGxAI has released an AI-driven genetic report that tailors GLP-1 therapies—including semaglutide brands Ozempic® and Wegovy®—to each patient’s genome, flagging high-risk variants and delivering actionable dosing or alternative-drug guidance within minutes via EHR integration.

•

•

•

Apr 15, 2025

PGxAI has launched Deneb, an AI pharmacogenetics model for biopharma and CROs that fuses molecular, physicochemical, and genomic data to deliver real-time PGx guidance, cutting trial costs and speeding drugs to market.

•

•

•

Feb 28, 2025

PGxAI has unveiled Vega, an AI-powered pharmacogenetics model that instantly converts a patient’s genomic data into drug-specific treatment recommendations, covering 1,200 drugs and 350 genes—vastly surpassing traditional panels.

•

•

•

Dec 24, 2024

PGxAI has raised $1.5 million to scale its AI-powered pharmacogenetics platform, funding upgrades to its VectorSearch and GenAI tools and deepening its partnership with InterSystems to deliver ultra-precise, genome-guided prescribing.

•

•

•

Dec 21, 2024

PGxAI captured the top prize at The Ventures Award—Silicon Valley’s roaming startup showcase—outshining hundreds of global contenders with its AI-powered pharmacogenomics platform. The tour now heads to Chicago on 7 Feb 2025 before expanding to other tech hubs worldwide.

•

•

•

Dec 19, 2024

PGxAI has launched Sirius, an AI-driven pharmacogenetics model that tailors drug choice, dosage, and interaction management to each patient’s genome, enabling ultra-precision prescribing for hospitals, labs, and CROs.

•

•

•

Jun 25, 2024

BioStrand (ImmunoPrecise) and PGxAI are partnering to build an AI-driven pharmacogenomics model on BioStrand’s LENSai platform to deliver personalized drug-response predictions and speed up LENSai API adoption.

•

•

•